Tilray Brands (NASDAQ:TLRY) Announces Earnings Results, Misses Estimates By $0.42 EPS

Tilray Brands (NASDAQ:TLRY) released its earnings results on Tuesday. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.42), Zacks reports. Tilray Brands had a negative return on equity of 7.84% and a negative net margin of 13.11%.The company had revenue of $281.71 million for the quarter, compared to analyst estimates of $246.30 million.

Here are the key takeaways from Tilray Brands’ conference call:

• Record fiscal-year performance: Revenue rose 11% to $915.5 million, adjusted EBITDA increased 11% to $61.1 million, and fourth-quarter adjusted EBITDA reached a record $31.9 million. Management guided to fiscal 2027 adjusted EBITDA of $68 million to $75 million.
• International cannabis remained a major growth engine: Medical cannabis revenue grew 34% to $84.9 million, with notable growth in Germany, the U.K., Poland, and Italy. Portugal utilization reached approximately 80%, while the company said expanded supply and faster permitting could support further growth.
• BrewDog expanded Tilray’s beverage platform: The acquisition contributed $51.1 million of fourth-quarter revenue and adds more than $200 million in annualized revenue, pubs, and international distribution. Tilray also expects to begin brewing and distributing Carlsberg brands in the U.S. on January 1, 2027.
• Profitability remains under pressure in parts of the portfolio: International cannabis faced approximately $21.1 million of price compression, beverage gross margin declined to 36% from 39%, and the legacy U.S. beer business experienced industry headwinds and a 17% organic fourth-quarter revenue decline excluding BrewDog. Management is targeting cost reductions and margin expansion to address these issues.
• Balance-sheet flexibility improved, but cash generation is not yet positive after investments: Tilray ended the year with $234.6 million in cash, marketable securities, and restricted cash, while net debt fell to less than $1 million. However, adjusted free cash flow remained negative at $86 million for the year, primarily due to BrewDog working-capital needs and strategic capital investments.

Tilray Brands Trading Up 0.1%

TLRY opened at $4.00 on Thursday. Tilray Brands has a one year low of $3.67 and a one year high of $23.20. The company has a market cap of $465.62 million, a P/E ratio of -3.71 and a beta of 1.89. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.66 and a current ratio of 2.79. The business’s 50-day simple moving average is $4.71 and its 200-day simple moving average is $6.31.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on TLRY shares. Weiss Ratings cut Tilray Brands from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 13th. TD Cowen reduced their target price on shares of Tilray Brands from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, July 14th. Roth Capital upgraded shares of Tilray Brands from a “neutral” rating to a “buy” rating and set a $10.00 price target for the company in a research note on Thursday, April 2nd. Finally, ATB Cormark Capital Markets reduced their price objective on shares of Tilray Brands from $9.50 to $9.00 and set a “sector perform” rating on the stock in a report on Thursday, April 2nd. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $11.00.

Hedge Funds Weigh In On Tilray Brands

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TLRY. Voloridge Investment Management LLC purchased a new position in Tilray Brands in the fourth quarter valued at approximately $824,000. Polymer Capital Management US LLC purchased a new stake in shares of Tilray Brands during the 4th quarter worth approximately $1,058,000. Engineers Gate Manager LP acquired a new position in shares of Tilray Brands in the 4th quarter valued at $126,000. Schonfeld Strategic Advisors LLC grew its position in shares of Tilray Brands by 4.5% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 144,358 shares of the company’s stock valued at $1,304,000 after buying an additional 6,182 shares during the last quarter. Finally, Jump Financial LLC purchased a new position in shares of Tilray Brands in the 4th quarter valued at $155,000. 9.35% of the stock is owned by institutional investors and hedge funds.

Tilray Brands News Summary

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Fiscal 2026 revenue reached a record $915 million, while adjusted EBITDA also set a record. International medical cannabis revenue increased 34%, and the BrewDog acquisition expanded Tilray’s beverage, hospitality and consumer-brand platform. Tilray fiscal 2026 results
• Positive Sentiment: Management forecast fiscal 2027 adjusted EBITDA of $68 million to $75 million, representing double-digit growth and signaling expected margin expansion. Tilray also reported approximately $235 million in cash, restricted cash and marketable securities, with net debt reduced to about $0.7 million. Tilray fiscal 2027 EBITDA guidance

About Tilray Brands

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.